Pharma BD Deal Intelligence
Zimmer Holdings' $13.3B cash-and-equity buy of Biomet built Zimmer Biomet into a global musculoskeletal-healthcare leader, pairing orthopedic implants with joint reconstruction products under one roof. A solid consolidation play that delivered scale, though not the transformative franchise-defining win the price tag implied.
Zimmer Holdings acquired Biomet in a cash and equity transaction valued at approximately $13.35 billion (rising to ~$14 billion at close), creating Zimmer Biomet, a global leader in musculoskeletal healthcare.
1.2M US cases/yr · $45.0B Global Orthopedic Devices Market (2014) · ~30% Combined US Large Joint Market Share
The Zimmer-Biomet merger created the world's largest pure-play orthopedic company, combining Zimmer's knee replacement leadership with Biomet's strength in hip replacement and sports medicine. Joint reconstruction (knee/hip arthroplasty) represents the largest segment, driven by aging demographics and growing obesity rates.
The orthopedic device market was an oligopoly: Zimmer Biomet, DePuy Synthes (J&J), Stryker, and Smith & Nephew controlled ~85% of large joint reconstruction. The merger required significant FTC divestitures. Integration was rocky, with supply chain disruptions and a DOJ investigation into the legacy Biomet FCPA issues. Zimmer Biomet has since stabilized and competes primarily with Stryker for market leadership.
Zimmer Holdings completed acquisition of Biomet for ~$13.35B in cash and stock, creating Zimmer Biomet Holdings.
Zimmer Biomet began integration with ~2,800 employee reductions to capture projected cost synergies.
Combined Q3 2016 net sales $1.76B, up 59.3% YoY, net earnings surging 45.5%. Reflects financial performance following Zimmer Holdings Inc.'s $13.3B acquisition of Biomet Inc..
Net EBIT synergies hit $225M by end of 2016, well above original $135M first-year target.
Integration exceeded synergy targets and created a top-3 global orthopedic company.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Zimmer Holdings Inc. / Biomet Inc. (this deal) | 2014 | $13.3B | 63 |
| Zimmer Holdings Inc. / Centerpulse AG | 2003 | $3.2B | 60 |
| Zimmer Holdings Inc. / Paragon 28, Inc. | 2025 | $1.1B | — |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Zimmer Holdings Inc. deals · Multiple (undisclosed) deals